First Tracks Biotherapeutics (NASDAQ:TRAX) Given “Buy” Rating at HC Wainwright

First Tracks Biotherapeutics (NASDAQ:TRAX)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $30.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 51.36% from the company’s current price.

A number of other research analysts have also recently commented on TRAX. Barclays started coverage on First Tracks Biotherapeutics in a report on Wednesday, April 22nd. They issued an “overweight” rating and a $40.00 price target on the stock. UBS Group initiated coverage on shares of First Tracks Biotherapeutics in a report on Tuesday, April 21st. They set a “buy” rating and a $45.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on shares of First Tracks Biotherapeutics in a research report on Thursday, April 23rd. They set an “overweight” rating and a $31.00 price objective on the stock. Piper Sandler initiated coverage on shares of First Tracks Biotherapeutics in a research report on Monday, May 4th. They set an “overweight” rating and a $54.00 target price for the company. Finally, Leerink Partners started coverage on shares of First Tracks Biotherapeutics in a research note on Friday, April 24th. They set an “outperform” rating and a $46.00 target price for the company. Eight research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, First Tracks Biotherapeutics has an average rating of “Moderate Buy” and an average price target of $38.25.

First Tracks Biotherapeutics Trading Up 0.2%

NASDAQ:TRAX opened at $19.82 on Wednesday. The firm’s 50-day simple moving average is $17.90. First Tracks Biotherapeutics has a 52 week low of $14.72 and a 52 week high of $26.80.